Axim Biotechnologies Inc (AXIM)

[Det_Robert_Thorne]

AXIM's 3Q/16 10-Q is a laugher. Way overvalued.

Less than $10K revenue, a $1.6M operating loss, and when the dividend on the preferred stock is figured in, a net loss of $3.3M.

Oh, yeah, and the OS has risen by about 5M shares in the past three months, to nearly 51.5M shares, which gives AXIM a market cap of nearly $510M, when it should be well less than $50M.

BTW, there is a new $850K convertible note on the books that can begin converting at $0.22/share in mid-March, 2017, and the noteholder, TL-66, LLC, has the option to lend another $4.2M.

The OS is going to start to balloon in the Spring of 2017.

https://www.sec.gov/Archives/edgar/data/1514946/000107878216003849/f10q093016_10q.htm

And the "pipeline" and patent? The patent is an extension of the same patent used by CanChew CBD gum, which has been selling since late 2013 or early 2014, and has never sold more than $400K per year, with revenue of less than $100K in 2015.